Status:
COMPLETED
Copeptin in the Diagnosis of Post-operative Insipidus Diabetes After Pituitary Surgery
Lead Sponsor:
CHU de Reims
Conditions:
Pituitary Surgery
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Endoscopic trans-sphenoidal pituitary endoscopic surgery is one of the main axes of management of tumours of the sellar region. Central diabetes insipidus is a frequent complication of endoscopic tra...
Detailed Description
Objective is to study the interest of copeptin dosage as an early predictive marker for the diagnosis of post-operatice diabetes insipidus in trans-sphenoidal endoscopic pituitary surgery.
Eligibility Criteria
Inclusion
- inclusion criteria : adult patient patient undergoing pituitary surgery for tumour of the sellar region patient consenting to participate to the study patient enrolled in the national healthcare insurance program
- exclusion criteria : Patient with preoperative diabetes insipidus. Patient undergoing pituitary surgery for suspicion of craniopharyngioma Patient undergoing pituitary surgery for pituitary metastases Patient under 18 years
Exclusion
Key Trial Info
Start Date :
January 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2024
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT04326569
Start Date
January 3 2022
End Date
March 18 2024
Last Update
June 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damien JOLLY
Reims, France